Jay R. Luly
President and CEO at Enanta Pharmaceuticals Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Enanta Pharmaceuticals Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Enanta Pharmaceuticals Inc. March 11, 202699.2%
-
Enanta Pharmaceuticals Inc. March 2, 202394.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 12, 2026 | Enanta Pharmaceuticals Inc. | Grant or award | +4,800 | — | — |
| Feb 12, 2026 | Enanta Pharmaceuticals Inc. | Grant or award | +15,200 | — | — |
| Feb 12, 2026 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −6,155 | $14.25 | $87,709 |
| Dec 5, 2025 | Enanta Pharmaceuticals Inc. | Open-market sale | −4,743 | $14.23 | $67,493 |
| Dec 1, 2025 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −1,885 | $14.12 | $26,616 |
| Feb 12, 2025 | Enanta Pharmaceuticals Inc. | Grant or award | +25,500 | — | — |
| Feb 12, 2025 | Enanta Pharmaceuticals Inc. | Open-market purchase | +45,000 | $5.69 | $256,050 |
| Feb 12, 2025 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −7,484 | $5.59 | $41,836 |
| Dec 6, 2024 | Enanta Pharmaceuticals Inc. | Open-market sale | −5,142 | $8.06 | $41,445 |
| Dec 1, 2024 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −3,829 | $8.60 | $32,929 |
| Feb 12, 2024 | Enanta Pharmaceuticals Inc. | Grant or award | +5,400 | — | — |
| Feb 12, 2024 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −1,584 | $12.41 | $19,657 |
| Dec 5, 2023 | Enanta Pharmaceuticals Inc. | Open-market sale | −7,230 | $9.63 | $69,625 |
| Dec 1, 2023 | Enanta Pharmaceuticals Inc. | Shares withheld for tax | −5,787 | $9.49 | $54,919 |
| Mar 13, 2023 | Enanta Pharmaceuticals Inc. | Option exercise | +27,912 | $14.00 | $390,768 |
Questions about Jay R. Luly
What boards is Jay R. Luly on?
Jay R. Luly sits on the board of Enanta Pharmaceuticals Inc.
What company is Jay R. Luly the CEO of?
Jay R. Luly is President and CEO of Enanta Pharmaceuticals Inc.
How long has Jay R. Luly served on boards?
Our records show at least 4 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.